SOPHiA GENETICS (NASDAQ:SOPH) CTO Abhimanyu Verma Sells 5,285 Shares of Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) CTO Abhimanyu Verma sold 5,285 shares of the company’s stock in a transaction on Monday, July 6th. The stock was sold at an average price of $5.10, for a total transaction of $26,953.50. Following the sale, the chief technology officer directly owned 192,171 shares of the company’s stock, valued at approximately $980,072.10. This trade represents a 2.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Abhimanyu Verma also recently made the following trade(s):

• On Thursday, June 25th, Abhimanyu Verma sold 6,944 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.51, for a total value of $38,261.44.

SOPHiA GENETICS Stock Up 1.9%

Shares of SOPH stock traded up $0.10 during trading hours on Tuesday, hitting $5.44. 284,563 shares of the company were exchanged, compared to its average volume of 187,273. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.90 and a current ratio of 2.06. The stock has a market capitalization of $456.36 million, a price-to-earnings ratio of -10.46 and a beta of 0.96. SOPHiA GENETICS SA has a one year low of $2.92 and a one year high of $6.30. The business’s 50-day simple moving average is $5.12 and its two-hundred day simple moving average is $4.96.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its quarterly earnings results on Tuesday, May 5th. The company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). The company had revenue of $21.69 million for the quarter, compared to analyst estimates of $20.40 million. SOPHiA GENETICS had a negative return on equity of 62.74% and a negative net margin of 44.48%.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on SOPH. BTIG Research reiterated a “buy” rating and issued a $8.00 price objective on shares of SOPHiA GENETICS in a research report on Monday, June 15th. Weiss Ratings restated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Tuesday, April 21st. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, SOPHiA GENETICS presently has an average rating of “Hold” and an average price target of $7.50.

Institutional Trading of SOPHiA GENETICS

Several hedge funds and other institutional investors have recently modified their holdings of the company. First Dallas Securities Inc. acquired a new position in SOPHiA GENETICS during the first quarter worth $50,000. Squarepoint Ops LLC acquired a new position in shares of SOPHiA GENETICS in the 3rd quarter valued at $49,000. Perkins Capital Management Inc. acquired a new stake in SOPHiA GENETICS during the fourth quarter valued at approximately $49,000. Quadrature Capital Ltd bought a new position in shares of SOPHiA GENETICS during the 4th quarter worth approximately $54,000. Finally, XTX Topco Ltd acquired a new position in SOPHiA GENETICS during the fourth quarter worth $55,000. 31.59% of the stock is currently owned by hedge funds and other institutional investors.

SOPHiA GENETICS News Summary

Here are the key news stories impacting SOPHiA GENETICS this week:

• Negative Sentiment: Chairman Jurgi Camblong sold 22,486 shares under a pre-arranged Rule 10b5-1 plan, and several other executives also sold stock the same day, including the CEO, CFO, CTO, and other insiders. While these sales were reportedly tied to tax withholding from vested equity awards, the breadth of selling can still pressure investor sentiment. Article: Chairman Jurgi Camblong sale filing
• Neutral Sentiment: The insider transactions were disclosed as routine 10b5-1 sales related to equity-award vesting, which makes them less concerning than discretionary selling, but they still add noise around the stock. Article: Philippe Menu sale filing
• Neutral Sentiment: SOPHiA GENETICS previously reported quarterly revenue of $21.69 million, topping expectations, even though earnings missed estimates. That mixed report still supports the stock’s broader recovery from its lows. Previous earnings report referenced in background

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.